First Trial of CRISPR-Edited T cells in Lung Cancer.

First Trial of CRISPR-Edited T cells in Lung Cancer. Trends Mol Med. 2020 Jun 12;: Authors: Lacey SF, Fraietta JA Abstract The clinical application of CRISPR-Cas9 gene editing has been eagerly awaited since the first description of the technique in 2013. Lu and colleagues now describe the treatment of 12 patients with nonsmall-cell lung cancer (NSCLC) with PD-1 gene-edited bulk autologous T cells, with results supporting both the feasibility and safety of gene editing in cell therapy. PMID: 32536469 [PubMed - as supplied by publisher]
Source: Trends in Molecular Medicine - Category: Molecular Biology Authors: Tags: Trends Mol Med Source Type: research